Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Roivant Sciences Ltd. Director's Dealing 2023

Dec 30, 2023

30587_dirs_2023-12-29_f23faf96-ee21-47fb-9337-0aea1dd26ed3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2023-12-27

Reporting Person: Ramaswamy Vivek (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-12-27 Common Shares M 275227 Acquired 55063337 Direct
2023-12-27 Common Shares F 133911 $11.58 Disposed 54929426 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-12-27 Capped Value Appreciation Rights $ M 611393 Disposed 2026-03-31 Common Shares (273490) Direct
2023-12-27 Capped Value Appreciation Rights $ M 251538 Disposed 2026-03-31 Common Shares (1737) Direct

Footnotes

F1: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2: On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023.

F3: On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023.

F4: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs.

F5: In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs.

F6: Includes an award of restricted stock covering Common Shares that is fully vested.